Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Open-source oncology calls for public-interest pathways for generic cancer drugs

Nature Reviews Clinical Oncology argues oncology needs public-interest pathways to test, authorize, and implement generic therapies with real patient value.

By Dr. Revathy Mohan V.R., MBBS · Oct 19, 2026 · 5 min read

Oncology·Nat Rev Onc

Spatially Fractionated Radiotherapy Reframes Dose Delivery for Bulky Tumors

A Nature Reviews overview examines spatially fractionated radiotherapy, its peak–valley dose design, early clinical activity, and unresolved planning…

Oct 19, 2026

Oncology·Nat Rev Onc

China Cancer Burden Rises as Screening and Survival Improve

China’s cancer burden is rising with ageing and better detection, while screening, treatment access, and survival continue to…

Oct 19, 2026

Oncology·Nat Rev Onc

Antibody-Drug Conjugates Reshape Gynaecologic Cancer Treatment

Nature review details how antibody-drug conjugates are changing ovarian, endometrial and cervical cancer care, with resistance, toxicity and…

Oct 19, 2026

Oncology·Front Immunol

Glioma model predicts survival benefit from adjuvant temozolomide

A multimodal transformer using pathology and MRI predicted postoperative temozolomide benefit in high-grade glioma and linked response to…

Oct 19, 2026

Oncology·Front Immunol

MDM2 inhibition activates p53 to improve human CD8 T-cell antitumor function

Transient MDM2 inhibition raised p53 in human CD8+ T cells, promoted memory-like states, reduced exhaustion, and improved engineered…

Oct 19, 2026

Oncology·Nature

AI consultation prep lowers oncology clinician workload in real-world study

A real-world oncology usability study found AI-generated consultation prep reduced clinician workload and saved time, though summary completeness…

Oct 19, 2026

Oncology·NLM Alerts

PINK1 Mitophagy May Shape Lung Cancer and KRAS Therapy Response

A Science Advances study examines PINK1-mediated mitophagy in lung cancer initiation and its potential impact on KRAS-targeted therapy.

Oct 19, 2026

Oncology·JCI

METTL1 drives pancreatic cancer growth through valine tRNA modification

METTL1 overexpression in pancreatic ductal adenocarcinoma supports valine tRNA modification, mitochondrial respiration, and tumor growth.

Oct 19, 2026

Oncology·Lan GH

Cancer Detection With NMR Metabolomics and Glycomics in Nonspecific Symptoms

Supplementary information for a Lancet Global Health study on NMR metabolomics and glycomics in cancer detection among patients…

Oct 18, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.